Abstract:The establishment of primary tumor cells in distant organs, termed metastasis, is the principal cause of cancer mortality and is a crucial therapeutic target in oncology. Thus, it is critical to establish a better understanding of metastatic progression for the future development of improved therapeutic approaches. Indeed, such development requires insight into the timing of tumor cell dissemination and seeding of distant organs resulting in occult lesions. Following dissemination of tumor cells from the primary tumor, they can reside in niches in distant organs for years or decades, following which they can emerge as an overt metastasis. This timeline of metastatic dormancy is regulated by interactions between the tumor, its microenvironment, angiogenesis, and tumor antigen-specific T-cell responses. An improved understanding of the mechanisms and interactions responsible for immune evasion and tumor cell release from dormancy would help identify and aid in the development of novel targeted therapeutics. One such mediator of dormancy is myeloid derived suppressor cells (MDSC), whose number in the peripheral blood (PB) or infiltrating tumors has been associated with cancer stage, grade, patient survival, and metastasis in a broad range of tumor pathologies. Thus, extensive studies have revealed a role for MDSCs in tumor escape from adoptive and innate immune responses, facilitating tumor progression and metastasis; however, few studies have considered their role in dormancy. We have posited that MDSCs may regulate disseminated tumor cells resulting in resurgence of senescent tumor cells. In this review, we discuss clinical studies that address mechanisms of tumor recurrence including from dormancy, the role of MDSCs in their escape from dormancy during recurrence, the development of occult metastases, and the potential for MDSC inhibition as an approach to prolong the survival of patients with advanced malignancies. We stress that assessing the impact of therapies on MDSCs versus other cellular targets is challenging within the multimodality interventions required clinically.

Immune evasion by dormant disseminated cancer cells: A Fermi paradox?

Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies

The current paradigm and challenges ahead for the dormancy of disseminated tumor cells

Breast Cancer Disseminated Tumor Cells: Do They Stay and Fight or Run and Hide?

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Finding the needle in the haystack

Immune Evasion through Competitive Inhibition: the Shielding Effect of non-Stem Cancer Cells

How Modulation of the Tumor Microenvironment Drives Cancer Immune Escape Dynamics

Mechanisms of disseminated cancer cell dormancy: an awakening field

Immune evasion by cancer stem cells

Method to Isolate Dormant Cancer Cells from Heterogeneous Populations

Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces

How much do we know about the metastatic process?

Cracking the Codes behind Cancer Cells' Immune Evasion

Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3

The dormant cancer cell life cycle

The hallmarks of cancer immune evasion

Role of myeloid-derived suppressor cells in tumor recurrence

Examination of the role of mutualism in immune evasion

Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming